Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.43 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.43 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | MPI | P34949 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14337283 | 0.98 | KMT2A (0.44) | KMT2AGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL13448857 | 0.85 | L3MBTL1 (0.46) | KMT2AGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL14337459 | 0.78 | GRIN2D (0.38) | KMT2AGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL14337249 | 0.76 | GRIN2D (0.36) | KMT2AGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL14337243 | 0.71 | KMT2A (0.45) | KMT2AALDH1A1MAPTMPILMNA | |
| SCHEMBL14337288 | 0.71 | HRH3 (0.46) | KMT2AALDH1A1MAPTMPITSHR | |
| SCHEMBL8418576 | 0.71 | KMT2A (0.67) | KMT2AALDH1A1MAPTMPILMNA | |
| SCHEMBL8418574 | 0.71 | KMT2A (0.67) | KMT2AALDH1A1MAPTMPILMNA | |
| SCHEMBL20915092 | 0.71 | GRIN2D (0.67) | KMT2AGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL20915093 | 0.71 | GRIN2D (0.67) | KMT2AGRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350106-B1 | PHOSPHORESCENT IRIDIUM COMPLEXES | BOE TECHNOLOGY GROUP CO LTD (CN) | 2018-05-09 | — | — | EP | disclosed |
| US-7989580-B2 | Phosphorescent iridium complexes | GENERAL ELECTRIC COMPANY (US) | 2011-08-02 | — | — | US | disclosed |
| WO-2010051100-A1 | PHOSPHORESCENT IRIDIUM COMPLEXES | GENERAL ELECTRIC COMPANY (US) | 2010-05-06 | — | — | WO | disclosed |
| US-20100105852-A1 | PHOSPHORESCENT IRIDIUM COMPLEXES | GENERAL ELECTRIC COMPANY (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100105852-A1 | PHOSPHORESCENT IRIDIUM COMPLEXES | GENERAL ELECTRIC COMPANY (US) | 2010-04-29 | — | — | US | disclosed |
| EP-1008595-B1 | Olefin polymerization catalyst and process for olefin polymerization | MITSUI CHEMICALS INC (JP) | 2008-09-10 | — | — | EP | disclosed |
| US-7312284-B2 | Process for producing polar olefin copolymer and polar olefin copolymer obtained thereby | MITSUI CHEMICALS, INC. (JP) | 2007-12-25 | — | — | US | disclosed |
| US-7312284-B2 | Process for producing polar olefin copolymer and polar olefin copolymer obtained thereby | MITSUI CHEMICALS, INC. (JP) | 2007-12-25 | — | — | US | disclosed |
| EP-1832609-A2 | Process for producing a copolymer of a non-polar olefin and a polar olefin and the copolymer obtained thereby | Mitsui Chemicals, Inc. (JP) | 2007-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105852-A1 | PHOSPHORESCENT IRIDIUM COMPLEXES | IGF1R, IRS1, IGF2R | KMT2A 1451/4885GRIN2D 2741/4885GRIN3B 2329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.